Improvement of Cognitive Indicators in Male Monkeys Exposed to Extremely Low-Frequency Electromagnetic Fields.

Today, the production of extremely low-frequency electromagnetic fields (ELF-EMFs) has significantly increased. This study aimed to investigate the effect of the ELF-EMFs on the structure and function of the brain in male rhesus monkeys in terms of visual learning (VL), visual memory (VM), and visual working memory (VWM). To conduct the study, four monkeys were selected, of whom two monkeys were irradiated by 12-Hz ELF-EMFs with a magnitude of 0.7 microtesla, and two monkeys were tested without irradiation (control group). A blood sample was taken in three stages, namely pre- and post-irradiated and the recovery phases. Changes in the plasma levels of sodium, potassium, and adrenocorticotropic hormone (ACTH) were evaluated. Moreover, gene expression of N-methyl-D-aspartate (NMDA) receptors was assessed. The anatomical change of the brain's prefrontal area was measured by magnetic resonance imaging and Digital Imaging and Communications in Medicine LiteBox file. The abilities of VL, VM, and VWM significantly improved after the irradiation. Furthermore, the expression of the NMDA receptors gene and the plasma levels of sodium, potassium, and ACTH significantly enhanced after the irradiation. However, the prefrontal area was not significantly affected by the irradiation. No significant differences were observed in any of the studied factors in the control group. Our findings suggested that ELF-EMFs irradiation at 12 Hz positively affected VL and VWM. Consequently, 12-Hz ELF-EMFs irradiations can be widely applied to improve cognitive abilities in monkeys.

Hydroalcoholic extract of Rosemary (Rosmarinus officinalis L.) and its constituent carnosol inhibit formalin-induced pain and inflammation in mice.

The anti-inflammatory and anti-nociceptive properties of Rosmarinus officinalis L. (ROL) extract and its major constituent, carnosol in male NMRI mice (W:25-30 g) have been evaluated in the present study. Formalin (2%, 20 microL) was injected into the plantar portion of the hind paw and resulting pain and inflammation was studied for 60 min. The plant extract, carnosol and other drugs were administered intraperitoneally or subcutaneously 30 min before formalin injection. In a separate experiment, the effects of the extract and carnosol on plasma corticosterone levels and activity of the enzymes cyclooxygenase type 1 and 2 (COX1 and COX2) were investigated. Injection of different doses of ROL and carnosol reduced pain in the phase 2 of the formalin test, which was not inhibited by naloxone and/or memantine. In addition, pretreatment of the animals with ROL and/or carnosol reduces the formalin-induced inflammation. Furthermore, the extract and carnosol did not affect plasma corticosterone levels compared with the control group. Interestingly, both the extract and carnosol inhibited COX1 and COX2 activity. It could be concluded that ROL extract and carnosol suppressed pain and inflammation induced by formalin injection, which may be due to inhibition of COX1 and COX2 enzymes activity.

Increased serum IL-6 level time-dependently regulates hyperalgesia and spinal mu opioid receptor expression during CFA-induced arthritis.

Interleukin (IL)-6 is known to cause pro- and anti-inflammatory effects during different stages of inflammation. Recent therapeutic investigations have focused on treatment of various inflammatory disorders with anti-cytokine substances. As a result, the aim of this study was to further elucidate the influence of IL-6 in hyperalgesia and edema during different stages of Complete Freund's Adjuvant (CFA)-induced arthritis (AA) in male Wistar rats. AA was induced by a single subcutaneous injection of CFA into the rats' hindpaw. Anti-IL-6 was administered either daily or weekly during the 21 days of study. Spinal mu opioid receptor (mOR) expression was detected by Western blotting. Daily and weekly treatment with an anti-IL-6 antibody significantly decreased paw edema in the AA group compared to the AA control group. Additionally, daily and weekly anti-IL-6 administration significantly reduced hyperalgesia on day 7 in the AA group compared to the AA control group; however, there were significant increases in hyperalgesia in the antibody-treated group on days 14 and 21 compared to the AA control group. IL-6 antibody-induced increases in hyperalgesia on the 14th and 21st days after CFA injection correlated with a time-dependent, significant reduction in spinal mOR expression during anti-IL-6 treatment. Our study confirmed the important time-dependent relationship between serum IL-6 levels and hyperalgesia during AA. These results suggest that the stages of inflammation in AA must be considered for anti-hyperalgesic and anti-inflammatory interventions via anti-IL-6 antibody treatment.